Masimo Corporation (MASI) Price Prediction

Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions.

In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Masimo Corporation (MASI) is trading at $179.95 with a market cap of $9.42B and a rank of 953. The stock sits near the middle of its market segment in size, reflecting its established presence in healthcare monitoring. The near-term forecast shows an unchanged current price for 2026 on average at $179.95 with neutral sentiment, while going forward the averages rise as the outlook broadens.

From 2027 onward, the forecasted averages point to a stronger upward trajectory, indicating bullish potential ahead. By 2030, the average forecast reaches $309.54, and by 2050 it climbs to $1,445.86, suggesting meaningful, long-run upside despite the inherent uncertainty of any forecast.

Over the multi-year horizon, the forecast shows a clear bullish tilt with rising averages and substantial upside potential. The 2026 forecast lists an average of $179.95 with a min of $127.40 and a max of $243.76 (ROI 0%, Neutral). By 2027 the average is $241.09 (ROI 34%), rising to $272.01 (ROI 51.2%) in 2028 and $278.18 (ROI 54.6%) in 2029.

The 2030 average is $309.54 (ROI 72%), and 2031–2035 show continued gains with averages of $342.03, $373.39, $459.75, and $526.03 respectively, all with bullish sentiment. The long horizon extends to 2040 with an average of $809.92 (ROI 350.1%) and a max of $1,235.98, and to 2050 with an average of $1,445.86 (ROI 703.5%) and a max of $2,364.86, both with bullish sentiment. These figures illustrate a sustained upward trajectory, though as with all forecasts, they are estimates and not guarantees.

The maximum forecast path reaches levels above $2,000 later in the decade, reflecting extended upside potential under favorable conditions, while the range of possible outcomes remains wide given market dynamics.